Shafik Hanna-Moussa, MD
Interventional Cardiology · Longview, TXNPI 1306850227
Payments from drug & device makers
Across 430 payments — averaging $78.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$14K
- Edwards Lifesciences$5K
- Penumbra, Inc.$4K
- Inari Medical, Inc.$3K
- Abiomed$2K
- Abbott$2K
- plus $5K from 32 others
What the payments were for
- Travel & lodging$20,64961%
- Food & beverage$13,30539%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 91 | $13,559 |
| Edwards Lifesciences | 38 | $4,754 |
| Penumbra, Inc. | 12 | $4,224 |
| Inari Medical, Inc. | 21 | $2,517 |
| Abiomed | 17 | $1,796 |
| Abbott | 21 | $1,700 |
| Shockwave Medical, Inc | 13 | $893 |
| Philips North America LLC | 18 | $776 |
| Stryker | 12 | $478 |
| Johnson & Johnson | 25 | $378 |
| Cardiovascular Systems Inc. | 11 | $325 |
| W. L. Gore & Associates, Inc. | 9 | $276 |
| Amgen | 19 | $264 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $250 |
| Boston Scientific | 10 | $212 |
| E.r. Squibb & Sons, L.L.C. | 26 | $207 |
| Novartis | 10 | $166 |
| Alnylam Pharmaceuticals Inc. | 1 | $123 |
| Bard Peripheral Vascular, Inc. | 5 | $120 |
| Cook Medical LLC | 10 | $112 |
| Merck | 6 | $111 |
| Chiesi USA, Inc. | 1 | $91 |
| Pfizer | 6 | $77 |
| Angiodynamics, Inc. | 3 | $70 |
| AstraZeneca | 5 | $63 |
| Impulse Dynamics (USA) Inc. | 1 | $57 |
| Boehringer Ingelheim | 4 | $56 |
| Heartflow, Inc. | 1 | $48 |
| Irhythm Technologies, Inc. | 3 | $41 |
| Bayer | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Biotronik Inc. | 2 | $30 |
| Cardiva Medical, Inc. | 1 | $25 |
| Amneal Pharmaceuticals LLC | 2 | $25 |
| Terumo Medical Corporation | 1 | $21 |
| Gilead | 1 | $17 |
| Altathera Pharmaceuticals LLC | 1 | $16 |
| Venturemed Group, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$8,796
- Indigo System$3,794
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,193
- FLOWTRIEVER CATHETER, S$2,056
- CT THROMBECTOMY SYSTEM KIT$2,056
- Impella$1,409
- PERCLOSE PROGLIDE$936
- CoreValve Evolut$910
- VenaSeal$729
- Micra$621
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$588
- (6582) Visions 035$304
- Penumbra System$146
- JETi All In One Non-Sterile Kit$142
- ARTIX MT$140
- CARDIOFORM Septal Occluder$127
- AMVUTTRA$123
- VENACORE THROMBECTOMY CATHETER$120
- IN.PACT Admiral$120
How this compares
$33,963 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 121 | $117,096 |
| XareltoRivaroxaban | 67 | $79,968 |
| EntrestoSacubitril/Valsartan | 28 | $40,407 |
| Repatha SureclickEvolocumab | 40 | $23,668 |
| BrilintaTicagrelor | 12 | $14,642 |
| Ranolazine ErRanolazine | 59 | $5,096 |
| ClopidogrelClopidogrel Bisulfate | 246 | $2,852 |
| ZypitamagPitavastatin Magnesium | 12 | $2,626 |
| Atorvastatin Calcium | 218 | $2,162 |
| Metoprolol Tartrate | 218 | $1,577 |
| Cilostazol | 50 | $1,286 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 110 | $1,081 |
| Potassium Chloride | 52 | $1,064 |
| Carvedilol | 131 | $1,057 |
| Metoprolol Succinate | 51 | $934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $77 | $117,096121 claims |
| Johnson & JohnsonXarelto | $378 | $79,96867 claims |
| NovartisEntresto | $166 | $40,40728 claims |
| AstraZenecaBrilinta | $63 | $14,64212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Longview
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.